Simplex Trading’s Checkpoint Therapeutics CKPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-900
Closed -$3K 8747
2025
Q1
$3K Sell
900
-22,000
-96% -$73.3K ﹤0.01% 7787
2024
Q4
$73K Buy
22,900
+17,900
+358% +$60.7K ﹤0.01% 5479
2024
Q3
$11K Sell
5,000
-2,000
-29% -$4.62K ﹤0.01% 7115
2024
Q2
$15K Sell
7,000
-5,700
-45% -$10.1K ﹤0.01% 7115
2024
Q1
$26K Sell
12,700
-13,300
-51% -$26.5K ﹤0.01% 6859
2023
Q4
$59K Buy
26,000
+24,500
+1,633% +$53.3K ﹤0.01% 5927
2023
Q3
$2K Sell
1,500
-5,000
-77% -$11.4K ﹤0.01% 8053
2023
Q2
$16K Sell
6,500
-30,200
-82% -$82.5K ﹤0.01% 6962
2023
Q1
$82K Buy
36,700
+34,700
+1,735% +$174K ﹤0.01% 5374
2022
Q4
$10K Buy
2,000
+1,120
+127% +$8.07K ﹤0.01% 7517
2022
Q3
$9K Sell
880
-4,540
-84% -$54.1K ﹤0.01% 8303
2022
Q2
$55K Sell
5,420
-2,400
-31% -$31.4K ﹤0.01% 6359
2022
Q1
$138K Buy
7,820
+6,100
+355% +$131K ﹤0.01% 5688
2021
Q4
$53K Buy
1,720
+440
+34% +$14.6K ﹤0.01% 7185
2021
Q3
$37K Hold
1,280
﹤0.01% 7875
2021
Q2
$37K Buy
1,280
+1,279
+127,900% +$35.4K ﹤0.01% 7990
2021
Q1
$1K Buy
+1
New +$34 ﹤0.01% 8539

Simplex Trading's CKPT Position: Q1 2024 in Review

Simplex Trading sold out of Checkpoint Therapeutics (CKPT) in Q1 2024, closing a stake of 13,611 shares — an estimated $27.2K sold.

Simplex Trading first reported a position in CKPT in Q1 2021 and held it in 9 quarters. The position peaked at $334K in Q4 2021. 40 funds tracked by Wall St. Rank hold CKPT as of Q1 2024.

  • Simplex Trading reported no remaining Checkpoint Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Simplex Trading sold 13,611 Checkpoint Therapeutics shares in Q1 2024, an estimated $27.2K.
  • Simplex Trading first reported a position in Checkpoint Therapeutics in Q1 2021 and held it in 9 quarters.
  • Simplex Trading's Checkpoint Therapeutics position peaked at $334K in Q4 2021.
  • 40 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2024.

Based on Simplex Trading's 13F filing for Q1 2024, filed 25 Apr 2024.